Valuation : Abpro Holdings, Inc.

Market Cap 1.2M 1.03M 973K 887K 1.66M 115M 1.67M 11.59M 4.46M 58.16M 4.5M 4.4M 185M P/E 2024
-2.41x
P/E 2025 -3.27x
Enterprise Value 1.28M 1.1M 1.04M 946K 1.77M 122M 1.78M 12.36M 4.76M 62.04M 4.8M 4.7M 197M EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
1 day+19.64%
1 week-13.91%
Current month-19.20%
1 month-20.85%
3 months-9.95%
6 months+71.67%
Current year-95.33%
1 week 0.19
Extreme 0.1943
0.25
1 month 0.19
Extreme 0.1939
0.25
Current year 0.09
Extreme 0.0866
5.08
1 year 0.09
Extreme 0.0866
8.25
3 years 0.09
Extreme 0.0866
390
5 years 0.09
Extreme 0.0866
390
10 years 0.09
Extreme 0.0866
390
Date Insider Type Main position Quantity % Market Cap. Importance
31/07/25 Buy

Chief Executive Officer

72,035 0.1386%
25/07/25 Free

Director

60,600 0.1166%
25/07/25 Free

Director

60,600 0.1166%
Change 5-day change 1-year change 3-year change Capi.($)
+19.64%-13.91%-96.09%-99.94% 1.2M
-0.32%-5.61%-4.12%+9.89% 46.05B
-2.08%-3.57%+402.72%+533.09% 43.59B
+0.12%-5.27%+39.94%+20.50% 42.35B
-2.62%-5.76%+8.88%+77.44% 38.86B
-1.26%-3.37%+11.87%+40.55% 32.24B
+0.16%-3.65% - - 17.16B
-0.54%-1.72%+22.34%+115.10% 16.28B
+0.54%-1.95%+11.41%+31.60% 14.32B
-1.92%-6.94%+78.12%+36.68% 13.03B
Average +1.17%-4.23%+52.78%+84.99% 26.39B
Weighted average by Cap. -1.00%-5.04%+86.44%+128.40%

Financials

2024 2025
Net sales 183K 157K 148K 135K 253K 17.5M 255K 1.77M 681K 8.87M 687K 672K 28.19M -
Net income -7.23M -6.22M -5.87M -5.35M -9.99M -691M -10.08M -69.89M -26.9M -351M -27.16M -26.56M -1.11B -2.89M -2.49M -2.35M -2.14M -4M -276M -4.03M -27.95M -10.76M -140M -10.86M -10.62M -445M
Net Debt 478K 411K 388K 353K 661K 45.7M 667K 4.62M 1.78M 23.18M 1.79M 1.76M 73.63M 80K 68.8K 64.91K 59.14K 111K 7.65M 112K 773K 298K 3.88M 300K 294K 12.32M
Logo Abpro Holdings, Inc.
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
2
Date Price Change Volume
10/09/26 $0.2034 -13.02% 2,812
09/09/26 $0.2339 +6.30% 18,881
08/09/26 $0.2200 -4.06% 6,558
03/09/26 $0.2293 +4.23% 3,458
02/09/26 $0.2200 -.--% 5,452

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABPO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!